Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules

Vaccine

Volumn 29, Issue 40, 2011, Pages 6823-6829

  Fraternale, Alessandra ^a   Paoletti, Maria Filomena ^a   Dominici, Sabrina ^a   Buondelmonte, Costantina ^a   Caputo, Antonella ^b   Castaldello, Arianna ^b   Tripiciano, Antonella ^c,d   Cafaro, Aurelio ^d   Palamara, Anna Teresa ^e,f   Sgarbanti, Rossella ^g   Garaci, Enrico ^h   Ensoli, Barbara ^d   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f IRCCS SAN RAFFAELE PISANA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antigen presenting cells; Intracellular redox state; Macrophages; Pro GSH molecules; Tat based vaccine; Th1 Th2 immune responses

Indexed keywords

ACETYLCYSTEINE; GAMMA INTERFERON; GLUTATHIONE C4; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 2; MERCAPTAMINE; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOMODULATION; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN CELL; TH1 CELL; TH2 CELL;

ACETYLCYSTEINE; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CYSTEAMINE; EPITOPE MAPPING; FEMALE; GLUTATHIONE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; PRODRUGS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TH1 CELLS; TH2 CELLS;

EID: 80052316843     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.101     Document Type: Article

References (31)

1. Short S., Merkel B.J., Caffrey R., McCoy K.L. Defective antigen processing correlates with a low level of intracellular glutathione. Eur J Immunol 1996, 26(12):3015-3020.
2. Murata Y., Shimamura T., Tagami T., Takatsuki F., Hamuro J. The skewing to Th1 induced by lentinan is directed through the distinctive cytokine production by macrophages with elevated intracellular glutathione content. Int Immunopharmacol 2002, 2(5):673-689.
3. Lemaire G., Guittet O., Vesin M.F., Lepoivre M., Cottet M.H. Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells. Mol Immunol 2009, 46(6):1100-1108.
4. Mego J.L. Role of thiols, pH, and cathepsin D in the lysosomal catabolism of serum albumin. Biochem J 1984, 218(3):775-783.
5. Kooistra T., Millard P.C., Lloyd J.B. Role of thiols in degradation of proteins by cathepsins. Biochem J 1982, 204(2):471-477.
6. Hamza T., Barnett J.B., Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 2010, 11(3):789-806.
7. Dobashi K., Aihara M., Araki T., Shimizu Y., Utsugi M., Iizuka K., et al. Regulation of LPS induced IL-12 production by IFN-gamma and IL-4 through intracellular glutathione status in human alveolar macrophages. Clin Exp Immunol 2001, 124(2):290-296.
8. Fraternale A., Paoletti M.F., Dominici S., Caputo A., Castaldello A., Millo E., et al. The increase in intra-macrophage thiols induced by new pro-GSH molecules directs the Th1 skewing in ovalbumin immunized mice. Vaccine 2010, 28(48):7676-7682.
9. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Buttò S., et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006, 20(18):2245-2261.
10. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27(25-26):3306-3312.
11. Caputo A., Gavioli R., Bellino S., Longo O., Tripiciano A., Francavilla V., et al. HIV Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol 2009, 28(5):285-334.
12. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A., Pavone Cossut M.R., Scoglio A., et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 2009, 182(5):2888-2897.
13. Tosi G., Meazza R., De Lerma Barbaro A., D'Agostino A., Mazza S., Corradin G., et al. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. Eur J Immunol 2000, 30(4):1120-1126.
14. Kittiworakarn J., Lecoq A., Moine G., Thai R., Lajeunesse E., Drevet P., et al. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem 2006, 281(6):3105-3115.
15. Pierleoni R., Menotta M., Antonelli A., Sfara C., Serafini G., Dominici S., et al. Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking. Mol Cell Biochem 2010, 345(1-2):105-118.
16. Garaci E., Palamara A.T., Ciriolo M.R., D'Agostini C., Abdel-Latif M.S., Aquaro S., et al. Intracellular GSH content and HIV replication in human macrophages. J Leukoc Biol 1997, 62(1):54-59.
17. Ensoli B., Bellino S., Tripiciano A., Longo O., Francavilla V., Marcotullio S., et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010, 5(11):e13540.
18. Palamara A.T., Brandi G., Rossi L., Millo E., Benatti U., Nencioni L., et al. New synthetic glutathione derivatives with increased antiviral activities. Antivir Chem Chemother 2004, 15(2):83-91.
19. Oiry J., Mialocq P., Puy J.Y., Fretier P., Dereuddre-Bosquet N., Dormont D., et al. Synthesis and biological evaluation in human monocyte-derived macrophages of N-(N-acetyl-l-cysteinyl)-S-acetylcysteamine analogues with potent antioxidant and anti-HIV activities. J Med Chem 2004, 47(7):1789-1795.
20. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002, 68(1):197-206.
21. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993, 67(1):277-287.
22. Castaldello A., Brocca-Cofano E., Voltan R., Triulzi C., Altavilla G., Laus M., et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 2006, 24(29-30):5655-5669.
23. Perkins F.T. A ready Reckoner for the calculation of geometric mean antibody titre. J Gen Microbiol 1958, 19(3):540-541.
24. Péterfly F., Kuusela P., Mäkelä O. Affinity requirements for antibody assays mapped by monoclonal antibody. J Immunol 1983, 130(4):1809-1813.
25. Lefeber D.J., Benaissa-Trouw B., Vliegenthart J.F., Kamerling J.P., Jansen W.T., Kraaijeveld K., et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines protein related to Streptococcus pneumoniae type 3. Infect Immun 2003, 71(12):6915-6920.
26. Koike Y., Hisada T., Utsugi M., Ishizuka T., Shimizu Y., Ono A., et al. Glutathione redox regulates airway hyperresponsiveness and airway inflammation in mice. Am J Respir Cell Mol Biol 2007, 37(3):322-329.
27. Alam K., Ghousunnissa S., Nair S., Valluri V.L., Mukhopadhyay S. Glutathione-redox balance regulates c-rel-driven IL-12 production in macrophages: possible implications in antituberculosis immunotherapy. J Immunol 2010, 184(6):2918-2929.
28. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J immunol 1995, 25(3):823-829.
29. Cafaro A., Macchia I., Maggiorella M.T., Titti F., Ensoli B. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Adv Exp Med Biol 2009, 655:189-242.
30. Fonseca D.E., Kline J.N. Use of CpG oligonucleotides in treatment of ashma and allergic disease. Adv Drug Deliv Rev 2009, 61(3):256-262.
31. Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 2008, 26(5):727-737.